AbbVie M19-130
Brief description of study
The purpose of this study is to see if the study drugs, elsubrutinib (ABBV-105), upadacitinib (ABT-494), or both elsubrutinib (ABBV-105) and upadacitinib (ABT-494) in combination (ABBV-599) are safe, tolerable, and effective in treating moderately to severely active systemic lupus erythematosus (SLE).
Clinical Study Identifier: s19-01634
ClinicalTrials.gov Identifier: NCT03978520
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
